Panitumumab in combination with FEC 100 (5-fluorouracil, epidoxorubicin, cyclophosphamide) followed by docetaxel (T) in patients with operable, triple-negative breast cancer (TNBC): Preliminary results of a multicenter neoadjuvant pilot phase II study.
J. Nabholtz
No relevant relationships to disclose
B. Weber
No relevant relationships to disclose
M. Mouret-Reynier
No relevant relationships to disclose
J. Gligorov
No relevant relationships to disclose
B. P. Coudert
No relevant relationships to disclose
L. Vanlemmens
No relevant relationships to disclose
T. Petit
No relevant relationships to disclose
O. Tredan
No relevant relationships to disclose
I. Van Praagh-Doreau
No relevant relationships to disclose
P. Dubray-Longeras
No relevant relationships to disclose
J. Ferriere
No relevant relationships to disclose
B. Nayl
No relevant relationships to disclose
N. Tubiana-Mathieu
No relevant relationships to disclose
C. Jouannaud
No relevant relationships to disclose
H. Devaud
No relevant relationships to disclose
C. Abrial
No relevant relationships to disclose
E. Planchat
No relevant relationships to disclose
N. Chalabi
No relevant relationships to disclose
F. M. Penault-Llorca
No relevant relationships to disclose
P. J. M. Chollet
No relevant relationships to disclose